Microvast Powers the Next Generation of Electric Commercial Vehicles with Groundbreaking Battery Technology at IAA Transportation 2024
Microvast Holdings, Inc. (NASDAQ: MVST) (“Microvast”, the “Company”, “we” or “our”), a technology innovator that designs, develops, and manufactures lithium-ion battery solutions, is advancing the adoption of electric commercial vehicles by launching its latest high-performance battery solutions at IAA Transportation 2024. The new lineup includes the introduction of silicon-based HnSO Cells, Lithium Titanate Oxide (LTO) Cells, and the third-generation MV-I Pack, offering an unprecedented combination of energy density, safety, and sustainability.
Microvast’s advanced battery solutions are designed to meet the rigorous energy demands of commercial transportation, enabling manufacturers to accelerate their shift to cleaner, more efficient electric powertrains.
Technological highlights and new products at IAA Transportation 2024:
- HnSO Cells (introduction of silicon-based cell technology): With an energy density of 300 Wh/kg, these cells provide high energy density, long cycle life (exceeding 4,000 cycles), and reduced total cost of ownership (TCO), making them ideal for long-range BEV and HEV applications.
- Lithium Titanate Oxide (LTO) Cells: Known for their enhanced safety and long cycle life of up to 20,000 cycles, LTO cells offer an energy density of 100Wh/kg, optimized for ultra high-power applications in challenging environments.
- Third Generation MV-I Pack: A robust, lightweight, turn-key solution featuring up to 200 Wh/kg energy density and over 5,000 full cycles. The MV-I Pack also integrates Microvast's 5th generation Battery Management System (BMS), ensuring compliance with ISO 26262 ASIL-C and advanced cybersecurity standards.
Additionally, Microvast introduces our fifth generation Battery Management System (BMS 5.0). BMS 5.0 is engineered for maximum functional safety, adhering to ISO 26262 ASIL-C standards and ISO/SAE 21434:2021 cybersecurity standards. This system ensures the highest levels of safety and security for electric vehicle operations.
Microvast’s latest comprehensive solutions for electric commercial vehicles contain an array of cell, module, and pack solutions, providing a one-stop solution for electric commercial vehicle applications with various operational profiles. With vertical integration from raw materials to turn-key solutions, Microvast offers scalable and versatile products tailored to meet the specific needs of different commercial operations.
“Our new battery technology marks a significant advancement for electric commercial vehicles, boasting increased energy density. The rapid charging capabilities facilitate enhanced mobility, while the cycle life is reliably extended. We’re driving the future of electric mobility with solutions that improve efficiency and reduce emissions,” said Dr. Wenjuan Mattis, CTO of Microvast.
Faster innovation, tailored customization, and exceptional quality: the future of e-mobility
Microvast’s vertically integrated model allows for complete control over all phases of development, from R&D to manufacturing. This unique model allows for faster innovation, tailored customization, and exceptional quality, providing commercial vehicle manufacturers with complete, scalable solutions that meet their specific operational needs.
Stefan Herr, Executive Vice President Microvast EMEA, added, “Our innovative battery technology is just the beginning. With a full-service approach, we provide end-to-end solutions for our customers — from tailored energy systems to ongoing support and optimization. We’re committed to delivering not just advanced technology, but a seamless, reliable partnership that ensures maximum performance and long-term success for electric commercial vehicle manufacturers and fleet operators alike.”
Reduced carbon emissions as a commitment to sustainability
Microvast’s mission is rooted in sustainability. The company is dedicated to advancing battery technology to accelerate the adoption of electric vehicles, reduce carbon emissions, and contribute to a greener planet. With over 17 years of manufacturing expertise, more than 30,000 installed battery systems worldwide, and a global presence in over 34 countries, Microvast acts as a trusted partner in the global transition to sustainable transportation.
About Microvast
Microvast is a global leader in providing battery technologies for electric vehicles and energy storage solutions. With a legacy of over 17 years, Microvast has consistently delivered cutting-edge battery systems that empower a cleaner and more sustainable future. The Company's innovative approach and dedication to excellence have positioned it as a trusted partner for customers around the world. Microvast was founded in 2006 and is headquartered in Stafford, Texas.
For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results; our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook,” or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding Microvast’s industry and market sizes, future opportunities for Microvast, and Microvast’s estimated future results. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic, and competitive uncertainties, and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915144080/en/
Contacts
Investor Relations Contact
Investor Relations Contact
ir@microvast.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom